8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Feb 6, 2026·SEC
Pyxis Oncology, Inc.(PYXS)Earnings, Financials & Key Ratios
PYXS•NASDAQ
$2.85
Price updated Jul 2, 2026
AboutPyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$14M-14.2%
- EBITDA-$80M+7.6%
- Net Income-$80M-3.0%
- EPS (Diluted)-1.28+3.0%
- Gross Margin82.77%-14.7%
- EBITDA Margin-576.63%-7.7%
- Operating Margin-609.18%-9.9%
- Net Margin-574.55%-20.0%
- ROE-91.43%-45.7%
PYXS Price & Volume
Pyxis Oncology, Inc. (PYXS) stock price & volume — 10-year historical chart
Loading chart...
Clinical Capital Exhaustion Threatens Pyxis Oncology Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent capital exhaustion
Key Thesis Takeaways
- Pyxis Oncology faces a precarious financial outlook as its reliance on non-recurring milestone payments fails to offset consistent, high-intensity R&D expenditures.
- The company's rapid erosion of total assets from $220.2 million in 2024Q1 to $64.3 million in 2026Q1 underscores a critical need for external financing to sustain its antibody-drug conjugate pipeline.
- Investors should remain cautious as the combination of negative operating margins and dwindling cash reserves suggests an imminent risk of significant shareholder dilution or liquidity failure.
Verdict Logic
the company's cash reserves have dwindled to a critical $7.2 million as of 2026Q1, which provides an insufficient buffer against ongoing quarterly operating losses and necessitates immediate, potentially dilutive, capital raises.
PYXS Growth Metrics
Pyxis Oncology, Inc. (PYXS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM16.56%
Return on Capital
10 Years-59.57%
5 Years-60.18%
3 Years-64.28%
Last Year-80.44%
PYXS Recent Earnings
Pyxis Oncology, Inc. (PYXS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 3/12 qtrs (100%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.37-5.7%
$0.35
Rev
—
$19,440
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$0.29+17.1%
$0.35
Rev
$11M+8730.4%
$125,000
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.35+2.8%
$0.36
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.30+16.7%
$0.36
Rev
$3M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.37vs $0.35-5.7% | —vs $19,440 |
| Q2 2026 | Mar 23, 2026 | $0.29vs $0.35+17.1% | $11Mvs $125,000+8730.4% |
| Q4 2025 | Nov 3, 2025 | $0.35vs $0.36+2.8% | — |
| Q3 2025 | Aug 14, 2025 | $0.30vs $0.36+16.7% | $3M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Pyxis Oncology, Inc. (PYXS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.85 | $180.56M | -2.23 | -14.17% | -574.55% | -91.43% | — | |
| $38.14 | $7.83B | -13.77 | — | — | -68.16% | — | |
| $28.92 | $2.91B | -8.79 | -4.26% | -156.36% | -68.97% | — | |
| $1.11 | $4.93M | -0.18 | — | — | -729.89% | — | |
| $37.08 | $2.21B | -5.21 | 48.03% | -639.84% | -34.11% | — | |
| $4.62 | $293.66M | -3.92 | 0.78% | -44.79% | -147.8% | — |
Compare PYXS vs Peers
Pyxis Oncology, Inc. (PYXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PYXS SEC Filings & Documents
Pyxis Oncology, Inc. (PYXS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PYXS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PYXS Frequently Asked Questions
Pyxis Oncology, Inc. (PYXS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Pyxis Oncology, Inc.'s revenue?
Pyxis Oncology, Inc. (PYXS) reported $13.9M in revenue for fiscal year 2025.
How fast is Pyxis Oncology, Inc. growing?
Pyxis Oncology, Inc. (PYXS) saw revenue decline by 14.2% over the past year.
Is PYXS profitable?
Pyxis Oncology, Inc. (PYXS) reported a net loss of $81.7M for fiscal year 2025.
Dividend & Returns
What is PYXS's return on equity?
Pyxis Oncology, Inc. (PYXS) has a return on equity (ROE) of -91.4%. Negative ROE indicates the company is unprofitable.
What is Pyxis Oncology, Inc.'s free cash flow?
Pyxis Oncology, Inc. (PYXS) had negative free cash flow of $67.0M in fiscal year 2025, likely due to heavy capital investments.